The Discovery of N-Cyclopropyl-4-Methyl-3-[6--(4-Methylpiperazin-1-Yl-4-Oxoquinazolin-3(4H)-Yl]Benzamide (Azd6703), a Clinical P38Alpha Map Kinase Inhibitor for the Treatment of Inflammatory Diseases
Brown, D.S., Cumming, J.G., Bethel, P., Finlayson, J., Gerhardt, S., Nash, I., Pauptit, R., Pike, K.G., Reid, A., Snelson, W., Swallow, S., Thompson, C.(2012) Bioorg Med Chem Lett 22: 3879
- PubMed: 22608965 
- DOI: https://doi.org/10.1016/j.bmcl.2012.04.116
- Primary Citation of Related Structures:  
4A9Y, 4AA0, 4AA4, 4AA5, 4AAC - PubMed Abstract: 
A novel, potent and selective quinazolinone series of inhibitors of p38α MAP kinase has been identified. Modifications designed to address the issues of poor aqueous solubility and high plasma protein binding as well as embedded aniline functionalities resulted in the identification of a clinical candidate N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3(4H)-yl]benzamide (AZD6703) ...